Pöldinger W
Int Pharmacopsychiatry. 1978;13(4):230-3. doi: 10.1159/000468344.
In 13 of 27 cases of persistent dyskinesia, treatment with amantadine, in an average dose of 300 mg, brought good to moderate improvement. In 14 patients who showed no response whatever, further treatment, with bromocriptine in doses raised gradually to a final daily dosage of 15 mg, was effective in four cases, though the improvement was generally only moderate. In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases. In a series of 20 patients with initial tremor due to neuroleptic therapy, on the other hand, the same treatment proved unsuccessful in the majority of cases. This is the converse of the experience gained with the classical antiparkinson agents, which have proved more effective against tremor induced by neuroleptics than against lithium-induced tremor.
在27例持续性运动障碍患者中,13例使用平均剂量为300毫克的金刚烷胺治疗后有显著至中度改善。14例对任何治疗均无反应的患者,使用溴隐亭进一步治疗,剂量逐渐增加至最终每日15毫克,4例有效,但改善程度一般仅为中度。在超过50%的锂治疗引起的初始震颤病例中,每日剂量为160 - 240毫克的氧烯洛尔产生了良好效果,另有少数病例有中度改善。另一方面,在一系列20例因抗精神病药物治疗引起初始震颤的患者中,同样的治疗在大多数病例中未成功。这与经典抗帕金森病药物的经验相反,经典抗帕金森病药物已被证明对由抗精神病药物引起的震颤比对锂引起的震颤更有效。